FDA Data Monitoring Cmte. Final Guidance Will Detail Role Of Statistician
This article was originally published in The Gray Sheet
Executive Summary
Clinical trial integrity may be best protected by relying on a blinded statistician to advise the sponsor on study design and an unblinded one to report to the data monitoring committee, Thomas Fleming, PhD, University of Washington, suggested during a Nov. 27 public meeting on FDA's draft guidance on clinical trial data monitoring committees in Bethesda, Maryland
You may also be interested in...
Drug-Coated Stents, Distal Protection Devices: DCRD Explicates DMC Benefits
Device firms employing data monitoring committees to evaluate clinical trials should ensure that DMCs operate under a clearly defined protocol, according to CDRH's Division of Cardiovascular & Respiratory Devices
Drug-Coated Stents, Distal Protection Devices: DCRD Explicates DMC Benefits
Device firms employing data monitoring committees to evaluate clinical trials should ensure that DMCs operate under a clearly defined protocol, according to CDRH's Division of Cardiovascular & Respiratory Devices
Data Monitoring Should Be Tailored To Device Trial Needs – Manufacturers
FDA's guidance on clinical trial data monitoring committees (DMCs) should make clear that device firms need not hire independent statisticians to perform interim analyses, Medtronic writes in Feb. 15 comments to FDA regarding the November 2001 draft guidance